Literature DB >> 34255218

Hsa_circ_0006404 and hsa_circ_0000735 Regulated Ovarian Cancer Response to Docetaxel Treatment via Regulating p-GP Expression.

Yan-Yan Chen1, Ying-Chun Tai2.   

Abstract

Several microRNAs (miRNAs) and circular RNAs (circRNAs) were reported to be involved in the Docetaxel (DTX) chemoresistance of cancer treatment, but the underlying mechanisms remain to be explored. In this study, we established cellular and animal models respectively to study the effect and underlying molecular mechanisms of the dysregulation of circRNA_0006404 and circRNA_0000735 in tumor response to DTX treatment. Quantitative real-time PCR was performed to measure the expression of circRNA_0006404, miR-346, circRNA_0000735, miR-526b, Dickkopf-related protein 3 (DKK3), and Dickkopf-related protein 4 (DKK4) mRNA. The expression of circRNA_0006404 and circRNA_0000735 was remarkably suppressed and activated in DTX-treated SKOV3-R cell lines, respectively. As revealed by luciferase assays, circRNA_0006404 and circRNA_0000735 was found to be respectively targeted by miR-346 and miR-526b, while DKK3 and DKK4 were respectively targeted by miR-346 and miR-526b. Moreover, the expression of DKK3 and DKK4, which were targets of miR-346 and miR-526b, respectively, was significantly altered along with the expression of p-GP. Furthermore, circ_0006404 shRNA and circRNA_0000735 shRNA showed remarkable efficiency in stimulating the expression of circRNA_0006404, miR-346, DKK3, circRNA_0000735, miR-526b, DKK4, and p-GP in cellular and animal models. Accordingly, the cell apoptosis and proliferation were apparently changed by circ_0006404 shRNA and circRNA_0000735 shRNA in both cellular and animal models. In summary, our study found the involvement of the circRNA_0006404/miR-346/DKK3/p-GP and circRNA_0000735/miR-546b/DKK4/p-GP axis in the tumor response to DTX. Both the up-regulation of circRNA_0006404 and down-regulation of circRNA_0000735 could inhibit the expression of p-GP in vivo and ex vivo, leading to the suppressed tumor response to DTX treatment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  DKK3; DKK4; Docetaxel resistance; Hsa_circ_0000735; Hsa_circ_0006404; Ovarian cancer; miR-346; miR-546b; p-GP

Mesh:

Substances:

Year:  2021        PMID: 34255218     DOI: 10.1007/s10528-021-10080-9

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  3 in total

Review 1.  Functional role of circular RNAs in cancer development and progression.

Authors:  Wei Lun Ng; Taznim Begam Mohd Mohidin; Kirti Shukla
Journal:  RNA Biol       Date:  2018-08-04       Impact factor: 4.652

2.  YM155 enhances docetaxel efficacy in ovarian cancer.

Authors:  Li-Jiao Hou; Xiao-Xiu Huang; Li-Na Xu; Yan-Yan Zhang; Na Zhao; Rong-Ying Ou; Wen-Feng Li; Wen-Ji Zhang; Qi-Wei Jiang; Yang Yang; Meng-Ning Wei; Jia-Rong Huang; Kun Wang; Meng-Ling Yuan; Zi-Hao Xing; Zhi Shi; Xiao-Jian Yan
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

3.  Synthetic Biology Based on Genetic Logic Circuit, Using the Expression of Drug Resistance, BCRP Pump in MCF-7 Cancer Cell Line.

Authors:  Marzieh Gerami; Modjtaba Emadi-Baygi; Mohammad Eshghi; Fatemeh Elahian; Razieh Heidari; Mehdi Hosseinzadeh
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

  3 in total
  4 in total

Review 1.  Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review.

Authors:  Gongwei Long; Siquan Ma; Runlin Shi; Yi Sun; Zhiquan Hu; Ke Chen
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

2.  Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.

Authors:  Liang Chen; Yarong Song; Teng Hou; Xuexiang Li; Lulin Cheng; Yunxue Li; Yifei Xing
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

Review 3.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 4.  Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Authors:  Xuehao Zhou; Xiang Ao; Zhaojun Jia; Yiwen Li; Shouxiang Kuang; Chengcheng Du; Jinyu Zhang; Jianxun Wang; Ying Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.